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This article is an executive summary of a report from the
Centers for Disease Control and Prevention Ventilator-
Associated Pneumonia Surveillance Definition Working
Group, entitled “Developing a new, national approach to sur-
veillance for ventilator-associated events” and published in
Critical Care Medicine. The full report provides a compre-
hensive description of the Working Group process and out-
come.
In September 2011, the Centers for Disease Control and
Prevention (CDC) convened a Ventilator-Associated Pneu-
monia (VAP) Surveillance Definition Working Group to or-
ganize a formal process for leaders and experts of key stake-
holder organizations to discuss the challenges of VAP
surveillance definitions and to propose new approaches to
VAP surveillance in adult patients (Table 1). The charges to
the Working Group were to:
1) Critically review a draft, streamlined VAP surveillance def-
inition developed for use in adult patients;
2) Suggest modifications to enhance the reliability and cred-
ibility of the surveillance definition within the critical care
and infection prevention communities;
3) Propose a final adult surveillance definition algorithm, to
be implemented in the CDC’s National Healthcare Safety
Network (NHSN), taking into consideration the potential
future use of the definition algorithm in public reporting,
interfacility comparisons, and pay-for-reporting and pay-
for-performance programs.
The Working Group’s surveillance definition algorithm,
which is referred to as the ventilator-associated events or VAE
surveillance definition algorithm, represents a purposeful de-
parture from VAP toward more general, objective measures
of conditions and complications occurring in patients on
mechanical ventilation (Figure 1; VAE surveillance protocol
available at: http://www.cdc.gov/nhsn/acute-care-hospital
/vae/index.html). The VAE surveillance definition algorithm
uses a tiered approach, moving from measures of ventilator-
associated conditions (VAC), to infection-related ventilator-
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table 1. VAP Surveillance Definition Working Group Organizations, Representatives and Federal Participants
Organization Representative(s)
American Association of Critical-Care Nurses Suzanne Burns and Beth Hammer
American Association for Respiratory Care Dean Hess
American College of Chest Physicians Robert Balk and David Gutterman
American Thoracic Society Nicholas Hill and Mitchell Levy
Association of Professionals in Infection Control and Epidemiology Linda Greene
Council of State and Territorial Epidemiologists Carole VanAntwerpen
Healthcare Infection Control Practices Advisory Committee Surveillance
Working Group Daniel Diekema
Infectious Diseases Society of America Edward Septimus
Society for Healthcare Epidemiology of America Michael Klompas
Society of Critical Care Medicine Clifford Deutschman, Marin Kollef, and Pamela Lipsett
U.S. Department of Health and Human Services, Office of Disease
Prevention and Health Promotion Don Wright
National Institutes of Health David Henderson
Centers for Disease Control and Prevention, Division of Healthcare
Quality Promotion
Scott Fridkin, Alice Guh, Shelley Magill, Teresa Horan,
others
associated complications (IVAC), to possible and probable
VAP.
The first tier of VAE surveillance, VAC, seeks to identify
episodes of sustained respiratory deterioration, and will cap-
ture both infectious and non-infectious conditions and com-
plications occurring in mechanically ventilated patients. VAC
is defined by a sustained period of worsening oxygenation
that immediately follows a baseline period of stability or im-
provement on the ventilator. To meet the VAC definition, a
mechanically ventilated patient must have at least 2 calendar
days of stable or decreasing daily minimum positive end-
expiratory pressure (PEEP) or fraction of inspired oxygen
(Fio2), followed by at least 2 days of increased daily minimum
PEEP or Fio2, where the increase in the daily minimum PEEP
is ≥3 cm H2O greater than the daily minimum PEEP during
the baseline period, or where the increase in the daily min-
imum Fio2 is ≥0.20 (or 20 percentage points in oxygen con-
centration) greater than the daily minimum Fio2 during the
baseline period. For example, if a patient’s daily minimum
Fio2 requirement on days 4 and 5 of mechanical ventilation
is 0.40, then the patient’s daily minimum Fio2 requirement
would need to be at least 0.60 on days 6 and 7 of mechanical
ventilation for the VAC definition to be met. The Working
Group’s decisions to set specific thresholds of 3 cm H20 and
0.20 (20 points) for the increases in PEEP and Fio2, respec-
tively, and to define a “sustained” increase as an increase
persisting for at least 2 calendar days, were based on expert
opinion of what criteria would likely identify clinically im-
portant events, while minimizing inadvertent inclusion of
other types of events resulting in transient changes in oxy-
genation—such as surgery or performance of other proce-
dures. Thresholds were also selected based upon published
data indicating that increases of ≥2.5 cm H2O in PEEP or
≥0.15 (15 points) in Fio2 sustained for at least 2 days were
associated with longer duration of mechanical ventilation,
ICU and hospital stays, and increased mortality.1 Subse-
quently, additional data have been published that support the
Working Group’s approach to VAC.2
The second tier, IVAC, attempts to identify the subset of
VACs that are potentially related to infection, as evidenced
by an abnormal white blood cell count or temperature and
initiation of a new antimicrobial agent. IVAC will likely cap-
ture patients with pulmonary infections and extrapulmonary
infections of sufficient severity to trigger respiratory deteri-
oration. The Working Group recognized the low predictive
value of an abnormal temperature or white blood cell count
in ICU patients, and Klompas and colleagues have shown
that the addition of fever or abnormal white blood cell count
to VAC definition does not substantially enhance the defi-
nition’s predictive value for death.2 Nevertheless, these are
objective and readily available signs that are frequently used
at the bedside to assess for the presence of infection. The
additional required criterion of starting a new antimicrobial,
where the new agent is continued for at least 4 days, may
add specificity and clinical credibility to the IVAC definition,
although data are needed.
The third tier, possible and probable VAP, attempts to zero
in on the subset of IVAC patients with respiratory infections
as manifested by objective evidence of purulent respiratory
secretions (where purulence is defined using quantitative or
semiquantitative criteria for the number of neutrophils on
Gram stain) and/or positive results of microbiological tests
performed on respiratory tract specimens. The possible VAP
definition is met with the presence of purulent secretions or
a positive lower respiratory tract culture (showing any
growth); the probable VAP definition requires purulent se-
cretions in addition to a positive lower respiratory tract cul-
ture meeting certain quantitative or semiquantitative thresh-
olds of pathogen growth. Organisms that are uncommonly
regarded as true VAP pathogens are excluded from possible
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figure 1. Ventilator-associated events surveillance definition algorithm. Available at: http://www.cdc.gov/nhsn/acute-care-hospital/vae
/index.html). Abbreviations: PEEP, positive end-expiratory pressure; Fio2, fraction of inspired oxygen; VAP, ventilator-associated pneumonia;
CFU, colony-forming units.
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and probable VAP culture criteria (with the exception of lung
tissue cultures): Candida spp., coagulase-negative staphylo-
cocci, and Enterococcus spp. The probable VAP definition can
also be met based upon the presence of a positive pleural
fluid culture, lung tissue with histopathological evidence of
infection, or positive diagnostic tests for Legionella or selected
respiratory tract viruses, without the concomitant require-
ment for purulent secretions. Although data have shown that
requiring purulent secretions or positive cultures in patients
who have met a VAC definition actually diminishes the as-
sociation between mortality and VAC,2 the Working Group
felt that it was important to provide definitions within the
VAE algorithm that more closely resemble VAP diagnostic
criteria used at the bedside.
This tiered approach is believed to be the most appropriate
approach in the current environment. It acknowledges lim-
itations in the ability to accurately identify VAP for surveil-
lance purposes—simply labeling an event “VAP” does not
make it so—and focuses instead on a more general measure
of complications of mechanical ventilation. This approach
may also reduce the likelihood of definition gaming or ma-
nipulation that could artificially lower event rates.
Two features of the VAE surveillance definition algorithm
are of particular note. First, radiographic evidence of pneu-
monia is not included as a criterion in any tier of the al-
gorithm, because of lack of specificity, and the subjectivity
inherent in facilities’ and individual providers’ practices in
ordering, performing, interpreting and reporting results of
chest radiographs. Second, only VAC and IVAC (and therefore
the overall VAE rate—the rate of all events meeting at least
the VAC definition—and the rate of all events meeting at least
the IVAC definition) are intended to be possible candidates
for future use in public reporting, interfacility comparisons,
and pay-for-performance programs. The VAC and IVAC def-
initions use criteria based on data anticipated to be available
from most mechanically ventilated patients and less subject
to manipulation or gaming. By contrast, the third definition
tier, possible and probable VAP, was developed to be used
only in internal quality improvement. These VAP definitions
include criteria based on documentation of purulent secre-
tions and/or microbiological findings and are more in keeping
with traditional clinical constructs of VAP. Because of the
substantial variability in the ordering and collection of lower
respiratory tract specimens, and in laboratory processing of
specimens and reporting of results, the Working Group de-
termined that it was not appropriate to include these data
elements in the VAC and IVAC definitions.
An iterative process for refining the definitions must be
ensured as experience using the definition algorithm accu-
mulates in the coming years. Although there was clearly a
need to establish a new surveillance approach in the NHSN,
there is also an urgent need to advance the science of sur-
veillance for VAP and other VAE. The VAE surveillance def-
inition algorithm should be studied, validated, and improved
in an ongoing manner. Evaluation and refinement of the
definitions should be conducted in collaboration with mem-
bers of the Working Group and other members of stakeholder
communities and organizations. The Working Group is al-
ready discussing potential modifications based on user feed-
back received during the first 3 months of VAE surveillance.
The VAP Surveillance Definition Working Group’s new
approach to surveillance in mechanically ventilated adults
acknowledges the current limitations in VAP diagnosis and
the potential benefit in focusing surveillance on an objective,
reliable, but more general measure of significant conditions
and complications that occur in patients on ventilators. VAE
surveillance was implemented by the CDC’s NHSN in Jan-
uary 2013. While much work remains, we believe this in-
novative approach to surveillance has significant potential to
increase the validity of comparisons among healthcare facil-
ities and, more importantly, to improve measurement and
patient safety in the ICU.
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